Founder and principal consultant David Knight, Ph.D. has more than 25 years of experience in the biotechnology industry. He has played key roles in the discovery and development of highly successful biopharmaceuticals and biotherapeutics including ReoPro™, Remicade™, Simponi™ and Stelara™.
Dr. Knight holds more than 80 issued US patents related to biopharmaceutical research, and has authored many articles for major journals.
Before founding Knight BioAdvisors, Dr. Knight was Vice President for Biopharmaceutical Research and a Distinguished Research Fellow with Johnson & Johnson. During a career spanning 25 years at Centocor, Inc. and Johnson & Johnson, Dr. Knight held numerous key positions, from bench scientist to head of a major research unit.
Specializing in therapeutic monoclonal antibodies, Dr. Knight pioneered early antibody engineering techniques, and established the commercial feasibility of recombinant antibody therapy with the marketing of ReoPro™, the first FDA approved recombinant antibody. His work on the discovery and development of Remicade™ led to its approval as the first-in-class anti-TNF biological therapy, and has been used to treat approximately two million patients to date.
Dr. Knight received his Ph.D. in Molecular Biology from the University of California, Berkeley, and completed a postdoctoral fellowship at Stanford University School of Medicine.